Voquezna is a drug owned by Phathom Pharmaceuticals Inc. It is protected by 2 US drug patents filed in 2023 out of which none have expired yet. Voquezna's patents will be open to challenges from 03 May, 2026. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 11, 2030. Details of Voquezna's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US7977488 | 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors |
Aug, 2028
(3 years from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9186411 | Pharmaceutical composition |
Aug, 2030
(5 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Voquezna's patents.
Latest Legal Activities on Voquezna's Patents
Given below is the list of recent legal activities going on the following patents of Voquezna.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Second letter to regulating agency to determine regulatory review period | 01 Mar, 2024 | US7977488 |
| Letter from FDA or Dept of Agriculture re PTE application | 24 Jan, 2024 | US7977488 |
| Initial letter Re: PTE Application to regulating agency | 17 Aug, 2023 | US7977488 |
| Change in Power of Attorney (May Include Associate POA) Critical | 16 Jun, 2023 | US9186411 |
| Email Notification Critical | 16 Jun, 2023 | US9186411 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Apr, 2023 | US9186411 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Dec, 2022 | US7977488 |
| Change in Power of Attorney (May Include Associate POA) Critical | 13 Jul, 2022 | US7977488 |
| Email Notification Critical | 13 Jul, 2022 | US7977488 |
| Correspondence Address Change Critical | 12 Jul, 2022 | US7977488 |
FDA has granted several exclusivities to Voquezna. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Voquezna, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Voquezna.
Exclusivity Information
Voquezna holds 3 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2027. Details of Voquezna's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 01, 2026 |
| New Chemical Entity Exclusivity(NCE) | May 03, 2027 |
| New Indication(I-948) | Jul 17, 2027 |
US patents provide insights into the exclusivity only within the United States, but Voquezna is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Voquezna's family patents as well as insights into ongoing legal events on those patents.
Voquezna's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Voquezna's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Aug 11, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Voquezna Generics:
There are no approved generic versions for Voquezna as of now.
Alternative Brands for Voquezna
There are several other brand drugs using the same active ingredient (Vonoprazan Fumarate) as Voquezna. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Phathom |
|
About Voquezna
Voquezna is a drug owned by Phathom Pharmaceuticals Inc. Voquezna uses Vonoprazan Fumarate as an active ingredient. Voquezna was launched by Phathom in 2023.
Approval Date:
Voquezna was approved by FDA for market use on 01 November, 2023.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Voquezna is 01 November, 2023, its NCE-1 date is estimated to be 03 May, 2026.
Active Ingredient:
Voquezna uses Vonoprazan Fumarate as the active ingredient. Check out other Drugs and Companies using Vonoprazan Fumarate ingredient
Dosage:
Voquezna is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 20MG BASE | TABLET | Prescription | ORAL |
| EQ 10MG BASE | TABLET | Prescription | ORAL |